NCT04133454View on ClinicalTrials.gov

Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT

PHASE1UnknownINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 10, 2019

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
Alzheimer Disease
Interventions
DRUG

AAV-hTERT

subjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration

Trial Locations (1)

250251

RECRUITING

IPS Arcasalud SAS, Zipaquirá

Sponsors
All Listed Sponsors
lead

Libella Gene Therapeutics

INDUSTRY